Non-Alcoholic Steatohepatitis (NASH) Epidemiology Analysis and Forecast to 2032

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Non-Alcoholic Steatohepatitis (NASH) Report Overview

In the 7MM, there were 22,036,613 diagnosed prevalent cases of NASH in 2022. The market is expected to grow at an AGR of more than 2% during 2022-2032. The Non-Alcoholic Steatohepatitis (NASH) market research report provides an overview of the risk factors, comorbidities, and global and historical epidemiological trends for NASH in the seven major markets. The report also includes a 10-year epidemiology forecast for the diagnosed prevalence of NASH.

NASH Market Outlook, 2022-2032 (Diagnosed Prevalent Cases)

NASH Market Outlook, 2022-2032 (Diagnosed Prevalent Cases)

Buy the Full Report for More Insights into the NASH Market Forecast

Download A Free Report Sample

The diagnosed prevalent cases of NASH are segmented by age and sex. Additionally, the forecast is further segmented based on fibrosis stage and cirrhosis type. This report also provides the historical and 10-year forecasted total and diagnosed prevalent cases of NAFLD.

Diagnosed Prevalent Cases (2022) 22,036,613 Cases
AGR (2022-2032) >2%
Forecast Period 2023 – 2032
Key Countries ·        France

·        Germany

·        Italy

·        Spain

·        The UK

·        Japan

·        The US

Key Age Segments ·        ≤18 years

·        18-29 years

·        30-39 years

·        40-49 years

·        50-59 years

·        60-69 years

·        70-79 years

·        ≥80 years

Key Sex Segments ·        Men

·        Women

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

NASH Market Segmentation by Countries

The key countries for diagnosed prevalent cases of NASH across the 7 MM are France, Germany, Italy, Spain, the UK, Japan, and the US. In 2022, Italy had the highest diagnosed prevalence, and the UK had the lowest diagnosed prevalence. From 2022- 2032, an increase in the diagnosed prevalence of NASH in the US, France, Spain, and the UK was partially driven by a steady increase in population. Increased diagnosis rates from 2022-2027 for all markets except Spain will also drive the market.

NASH Market Analysis by Countries, 2022 (%)

NASH Market Analysis by Countries, 2022 (%)

Buy the Full Report for More Country Insights into the NASH Market

Download A Free Report Sample

NASH Market Segmentation by Age

Based on age, the NASH market can be segmented into up to 18 years, 18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older. In 2022, in the US, France, Germany, Italy, and Spain, the diagnosed prevalent cases of NASH peaked at ages 60–69 years but in the UK, it peaked at ages 50–59 years.

NASH Market Analysis by Age (US, France, Germany, Italy, and Spain), 2022 (%)

NASH Market Analysis by Age (US, France, Germany, Italy, and Spain), 2022 (%)

Buy the Full Report for More Age Insights into the NASH Market

Download A Free Report Sample

NASH Market Segmentation by Sex

Based on sex, the NASH market can be segmented into men and women. In 2022, the number of diagnosed prevalent cases of NASH was higher in men than in women in the 7MM combined. France had the largest difference in the diagnosed prevalent cases of NASH between women and men while Japan had the smallest variation.

NASH Market Analysis by Sex, 2022 (%)

NASH Market Analysis by Sex, 2022 (%)

Full Report for More Sex Insights into the NASH Market

Download A Free Report Sample

Segments Covered in the Report

NASH Market Country Outlook (Diagnosed Prevalent Cases, 2022-2032)

  • France
  • Germany
  • Italy
  • Spain
  • The UK
  • Japan
  • The US

NASH Market Age Outlook (Diagnosed Prevalent Cases, 2022-2032)

  • ≤18 years
  • 18-29 years
  • 30-39 years
  • 40-49 years
  • 50-59 years
  • 60-69 years
  • 70-79 years
  • ≥80 years

NASH Market Sex Outlook (Diagnosed Prevalent Cases, 2022-2032)

  • Men
  • Women

Scope

Non-alcoholic steatohepatitis report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for NASH in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of NASH. The diagnosed prevalent cases of NASH are segmented by age and sex. Additionally, the forecast is further segmented based on fibrosis stage and cirrhosis type. This report also provides the historical and 10-year forecasted total and diagnosed prevalent cases of NAFLD.

Reasons to Buy

The NASH Epidemiology series will allow you to –

  • Develop business strategies by understanding the trends shaping and driving the global NASH markets.
  • Quantify patient populations in the global NASH markets to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for NASH therapeutics in each of the markets covered.
  • Understand the magnitude of the NASH population by age, sex, fibrosis stage, and cirrhosis type.

Table of Contents

  • 1 Non-Alcoholic Steatohepatitis: Executive Summary

    • 1.1 Catalyst
    • 1.2 Related reports
    • 1.3 Upcoming reports

  • 2 Epidemiology

    • 2.1 Disease background
    • 2.2 Risk factors and comorbidities
    • 2.3 Global and historical trends
    • 2.4 7MM forecast methodology.

      • 2.4.1 Forecast assumptions and methods.
      • 2.4.2 Forecast assumptions and methods: diagnosed prevalent cases of NAFLD.
      • 2.4.3 Forecast assumptions and methods: total prevalent cases of NAFLD
      • 2.4.4 Forecast assumptions and methods: diagnosed prevalent cases of NASH
      • 2.4.5 Forecast assumptions and methods: diagnosed prevalent cases of NASH by fibrosis stage.
      • 2.4.6 Forecast assumptions and methods: diagnosed prevalent cases of NASH with compensated and decompensated cirrhosis.

    • 2.5 Epidemiological forecast for non-alcoholic steatohepatitis (2022–32)

      • 2.5.1 Diagnosed prevalent cases of NASH.
      • 2.5.2 Age-specific diagnosed prevalent cases of NASH
      • 2.5.3 Sex-specific diagnosed prevalent cases of NASH
      • 2.5.4 Diagnosed prevalent cases of NASH by fibrosis stage.
      • 2.5.5 Diagnosed prevalent cases of cirrhosis attributable to NASH.

    • 2.6 Discussion

      • 2.6.1 Epidemiological forecast insight
      • 2.6.2 Obesity omission
      • 2.6.3 COVID-19 impact.
      • 2.6.4 Limitations of the analysis
      • 2.6.5 Strengths of the analysis

  • 3 Appendix

    • 3.1 Bibliography
    • 3.2 Primary research – high-prescriber survey
    • 3.3 About the Authors

      • 3.3.1 Epidemiologist
      • 3.3.2 Reviewers
      • 3.3.3 Vice President of Disease Intelligence and Epidemiology

  • 4 Contact Us

Table

Table 1: Summary of newly added data types

Table 2: Summary of updated data types

Table 3: Non-alcoholic fatty liver disease activity score

Table 4: Risk factors and comorbidities for CKD

Table 5: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: 7MM, diagnosed prevalent cases of NASH, both sexes, N, all ages, 2022 and 2032

Figure 2: 7MM, diagnosed prevalence of NASH, both sexes, %, all ages, 2012-32

Figure 3: 7MM, sources used to forecast the diagnosed prevalent cases of NAFLD

Figure 4: 7MM, sources used to forecast the total prevalent cases of NAFLD

Figure 5: 7MM, sources used to forecast the diagnosed prevalent cases of NASH

Figure 6: 7MM, sources used to forecast diagnosed prevalent cases of NASH by fibrosis stage

Figure 7: 7MM, sources used to forecast the diagnosed prevalent cases of NASH by cirrhosis type

Figure 8: 7MM, diagnosed prevalent cases of NASH, N, men and women, all ages, 2022

Figure 9: 7MM, diagnosed prevalent cases of NASH by age, N, men and women, 2022

Figure 10: 7MM, diagnosed prevalent cases of NASH by sex, N, all ages, 2022

Figure 11: 7MM, diagnosed prevalent cases of NASH by fibrosis stage, N, men and women, all ages, 2022

Figure 12: 7MM, diagnosed prevalent cases of cirrhosis attributable to NASH, N, men and women, all ages, 2022

Frequently asked questions

Non-Alcoholic Steatohepatitis (NASH) Epidemiology Analysis and Forecast to 2032 thematic reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Non-Alcoholic Steatohepatitis (NASH) Epidemiology Analysis and Forecast to 2032 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Non-Alcoholic Steatohepatitis (NASH) Epidemiology Analysis and Forecast to 2032 in real time.

  • Access a live Non-Alcoholic Steatohepatitis (NASH) Epidemiology Analysis and Forecast to 2032 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.